MARKET RADAR
SENSEX     NIFTY      Refresh
Moneycontrol.com India | Accounting Policy > Pharmaceuticals > Accounting Policy followed by AstraZeneca Pharma - BSE: 506820, NSE: ASTRAZEN
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > ACCOUNTING POLICY - AstraZeneca Pharma
AstraZeneca Pharma
BSE: 506820|NSE: ASTRAZEN|ISIN: INE203A01020|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
May 17, 17:00
799.50
-9.4 (-1.16%)
VOLUME 15,062
LIVE
NSE
May 17, 17:00
800.90
-6.9 (-0.85%)
VOLUME 31,862
« Mar 11
Accounting Policy Year : Mar '12
(i) Basis of preparation of financial statements
 
 The financial statements have been prepared and presented under the
 historical cost convention on the accrual basis of accounting and
 mandatory Accounting Standards (''AS'') prescribed by the Companies
 (Accounting Standards), Rules 2006 and the relevant provisions of the
 Companies Act, 1956, to the extent applicable.
 
 The Board of Directors at their meeting held on 23 February 2010 had
 approved the change in the company''s statutory accounting year from
 January- December to April- March. Accordingly, the previous period
 financial accounts are for a period of 15 months, i.e. from 1 January
 2010 to 31 March 2011 (the Period).
 
 (ii) Use of estimates
 
 The preparation of financial statements in conformity with generally
 accepted accounting principles requires management to make estimates
 and assumptions that affect the reported amounts of assets and
 liabilities and the disclosure of contingent liabilities on the date of
 the financial statements.  Actual results could differ from those
 estimates.  Any revision to accounting estimates is recognised
 prospectively in current and future years.
 
 (iii) Revenue recognition
 
 Revenue from sale of goods (including sale of scrap) is recognised on
 transfer of all significant risks and rewards of ownership to the
 buyer. The amount recognised as sale is exclusive of sales tax and net
 of trade discounts and sales returns. Sales are presented both gross
 and net of excise duty.
 
 Interest on deployment of surplus funds is recognised using the time
 proportion method, based on underlying interest rates.
 
 The Company derives its service income from services for clinical
 trials provided to its group companies and co-promotion services to its
 customers. The income from clinical trials is based on a ''cost plus''
 model as agreed with its group companies. As per the agreement, costs
 incurred internally are charged with a mark-up and those incurred
 externally are charged at actuals. Revenue from such services is
 recognised when the service is performed in accordance with agreement
 with the group companies. The income from co-promotion services is
 recognised when the service is performed in accordance with the
 agreement with the customer.
 
 Revenues which have not been billed, but have been accrued as per the
 terms of the contract with the customers are debited as unbilled
 revenue.
 
 The Company derives its rental income from group companies for the
 assets leased. Income is accrued based on the agreement entered.
 
 (iv) Fixed assets and capital work-in- progress
 
 Fixed assets are carried at cost of acquisition or construction less
 accumulated depreciation.  The cost of fixed assets includes freight,
 duties, taxes and other incidental expenses related to the acquisition
 or construction of the respective fixed assets. Borrowing costs
 directly attributable to acquisition or construction of those fixed
 assets which necessarily take a substantial period of time to get ready
 for their intended use are capitalised.  Intangible assets are recorded
 at their acquisition cost.
 
 The cost of the fixed assets not ready for their intended use before
 such date, are disclosed as capital work-in-progress.
 
 (v) Depreciation
 
 Depreciation on fixed assets is provided on the straight-line method,
 based on useful lives of assets as estimated by management.
 
 License for use and application of know-how and trademark are being
 amortised on straight-line method over its useful life of 60 months as
 specified in the contract, from the date it was available for use.
 
 Pro-rata depreciation is provided on all assets purchased and sold
 during the year. Assets costing individually Rs 5,000 or less are
 depreciated fully in the year of purchase.
 
 (vi) Impairment of assets
 
 The Company periodically assesses whether there is any indication that
 an asset or a group of assets comprising a cash generating unit may be
 impaired.  If any such indication exists, the Company estimates the
 recoverable amount of the asset. For an asset or group of assets that
 does not generate largely independent cash inflows, the recoverable
 amount is determined for the cash-generating unit to which the asset
 belongs. If such recoverable amount of the asset or the recoverable
 amount of the cash generating unit to which the asset belongs is less
 than its carrying amount, the carrying amount is reduced to its
 recoverable amount. The reduction is treated as an impairment loss and
 is recognised in the statement of profit and loss. If at the balance
 sheet date there is an indication that if a previously assessed
 impairment loss no longer exists, the recoverable amount is reassessed
 and the asset is reflected at the recoverable amount subject to a
 maximum of depreciable historical cost. An impairment loss is reversed
 only to the extent that the carrying amount of asset does not exceed
 the net book value that would have been determined, if no impairment
 loss had been recognised.
 
 (vii) Foreign exchange transactions
 
 Foreign exchange transactions are recorded using the exchange rates
 prevailing on the dates of the respective transactions. Exchange
 differences arising on foreign exchange transactions settled during the
 year are recognised in the statement of profit and loss for the year.
 
 Monetary assets and liabilities denominated in foreign currencies as at
 the balance sheet date are translated at the closing exchange rate on
 that date, the resultant exchange differences are recognised in the
 statement of profit and loss.
 
 (viii) Employee benefits
 
 Employees of the Company receive benefits from a provident fund, which
 is a defined benefit plan.  Both the employee and the Company make
 monthly contributions to the provident plan equal to a specified
 percentage of the employee''s salary. The Company contributes a part of
 the contributions to the AstraZeneca Pharma India Limited Management
 Staff Provident Fund Trust. The remaining portion is contributed to the
 government administrated pension fund. The rate at which the annual
 interest is payable to the beneficiaries by the trust is being
 administered by the government. The Company has an obligation to make
 shortfall, if any, between the returns from the investments of the
 trust and the notified interest rate.
 
 The Company has an arrangement with Life Insurance Corporation of India
 and ICICI Prudential Life Insurance Company to administer its
 superannuation scheme, which is a defined contribution scheme. The
 contributions to the said scheme are charged to the statement of profit
 and loss on an accrual basis.
 
 Liability for gratuity, which is a defined benefit, is provided based
 on an actuarial valuation at the balance sheet date, carried out by an
 independent actuary using projected unit credit method and charged to
 the statement of profit and loss. The Company makes contributions
 towards gratuity into the approved gratuity fund administered by ICICI
 Prudential Life Insurance Company.
 
 Liability for compensated absences, which is a defined benefit, is
 provided on the basis of an actuarial valuation and is charged to the
 statement of profit and loss on an accrual basis.
 
 (ix) Investments
 
 Long-term investments are stated at cost less any other-than-temporary
 diminution in value, determined separately for each individual
 investment.
 
 (x) Other current assets
 
 Stock of samples have been valued at cost, as in the ordinary course of
 business they have a realisable value at least equal to cost.
 
 (xi) Inventories
 
 Inventories are valued at lower of cost and net realisable value. Cost
 of inventories comprises all costs of purchase, costs of conversion and
 other costs incurred in bringing inventories to their present location
 and condition.
 
 The comparison of cost and net realisable value is made on an
 item-by-item basis.
 
 The net realisable value of work-in-progress is determined with
 reference to the selling prices of related finished goods.  Raw
 materials, packing materials and other supplies held for use in
 production of inventories are not written down below cost except in
 cases where material prices have declined, and it is estimated that the
 cost of the finished products will exceed their net realisable value.
 
 The provision for inventory obsolescence is assessed regularly based on
 estimated usage and shelf life of products.
 
 The methods of determination of cost of various categories of
 inventories are as follows:
 
 (i) Raw materials and packing materials
 
 Monthly moving weighted average cost
 
 (ii) Work-in-process and finished goods (Manufactured)
 
 Weighted average cost of production. Fixed production overheads are
 allocated on the basis of normal capacity of production facilities
 
 (iii) Traded goods Weighted average cost
 
 (iv) Goods in transit Actual cost
 
 (xii) Provisions and contingent liabilities
 
 The Company recognises a provision when there is a present obligation
 as a result of an obligating event that probably requires outflow of
 resources and a reliable estimate can be made of the amount of the
 obligation.
 
 The disclosure of contingent liability is made when, as a result of
 obligating events, there is a possible obligation or a present
 obligation that may, but probably will not, require outflow of
 resources.
 
 No provision or disclosure is made when, as a result of obligating
 events, there is a possible obligation or a present obligation where
 the likelihood of outflow of resources is remote.
 
 Provision for onerous contracts, i.e. contracts where the expected
 unavoidable cost of meeting the obligations under the contract exceed
 the economic benefits expected to be received under it, are recognised
 when it is probable that an outflow of resources embodying economic
 benefits will be required to settle a present obligation as a result of
 an obligating event based on a reliable estimate of such obligation.
 
 (xiii) Taxation
 
 Income-tax expense comprises current tax (i.e.  amount of tax for the
 year determined in accordance with the income-tax law) and deferred tax
 charge or credit (reflecting the tax effects of timing differences
 between accounting income and taxable income for the year). The
 deferred tax charge or credit and the corresponding deferred tax
 liabilities or assets are recognised using the tax rates that have been
 enacted or substantively enacted by the balance sheet date. Deferred
 tax assets are recognised only to the extent there is reasonable
 certainty that the assets can be realised in future; however, where
 there is unabsorbed depreciation or carried forward business loss under
 taxation laws, deferred tax assets are recognised only if there is a
 virtual certainty of realisation of such assets. Deferred tax assets/
 liabilities are reviewed as at each balance sheet date and written down
 or written-up to reflect the amount that is reasonably/ virtually
 certain (as the case may be) to be realised.
 
 The Company offsets, on a year on year basis, the current tax assets
 and liabilities, where it has a legally enforceable right and where it
 intends to settle such assets and liabilities on a net basis.
 
 (xiv) Earnings per share
 
 The basic earnings per share is computed by dividing the net profit
 attributable to equity shareholders for the year by the weighted
 average number of equity shares outstanding during the year.
 
 (xv) Leases
 
 Lease payments under operating lease are recognised as an expense in
 the statement of profit and loss on a straight line basis over the
 lease term.
 
 (xvi) Cash flow statement
 
 Cash flows are reported using indirect method, whereby net profits
 before tax are adjusted for the effects of transactions of a non-cash
 nature and any deferrals or accruals of past or future cash receipts or
 payments. The cash flows from regular revenue generating, investing and
 financing activities of the Company are segregated.
 
 (xvii) Research and development
 
 Research costs are expensed as incurred. Product development costs are
 expensed as incurred unless technical and commercial feasibility of the
 project is demonstrated, future economic benefits are probable, the
 Company has an intention and ability to complete and use or sell the
 product and the costs can be measured reliably.
 
 Terms and rights attached to equity shares
 
 The Company has only one class of share referred to as equity shares
 having par value of Rs. 2 each. Each holder of equity shares is entitled
 to one vote per share. The Company declares and pays dividends in
 Indian rupees. The dividend proposed by the Board of Directors is
 subject to the approval of the shareholders in the ensuing Annual
 General Meeting.
 
 During the year ended 31 March 2012, the amount of per share dividend
 recognized as proposed distributions to equity shareholders is Rs. 3.50
 per share (31 March 2011: Rs. 10 per share).
 
 In the event of liquidation of the Company, the holders of equity
 shares will be entitled to receive any of the remaining assets of the
 company, after distribution of all preferential amounts. However, no
 such preferential amounts exist currently. The distribution will be in
 proportion to the number of equity shares held by the shareholders.
 
Source : Dion Global Solutions Limited
Quick Links for astrazenecapharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.